Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group.

Krug UO, Koschmieder A, Gerss J, Serve H, Steffen B, Bug G, Schaich M, Brandts C, Rollig C, Ehninger G, Duehrsen U, Noppeney R, Berdel WE, Koschmieder S, Muller-Tidow C

Research article (journal)

Details about the publication

Journal: Blood (Blood)

Volume: 116

Issue: 21

Status: Published

Release year: 2010

Language in which the publication is written: English

Authors from the University of Münster

Berdel, Wolfgang Eduard	Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Gerß, Joachim	Institute of Biostatistics and Clinical Research (IBKF)
Koschmieder, Steffen	Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Koschmieder, Anja	Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Krug, Utz	Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group.

Details about the publication

Authors from the University of Münster

Operated by

Top-Links